Title: Improved Resection and Prolonged Overall Survival with PD-1-IRDye800CW Fluorescence Probe-Guided Surgery and PD-1 Adjuvant Immunotherapy in 4T1 Mouse Model
|
| Authors: Du, Y; Sun, T; Liang, XL; Li, Y; Jin, ZY; Xue, HD; Wan, YH; Tian, J
|
| Author Full Names: Du, Yang; Sun, Ting; Liang, Xiaolong; Li, Yuan; Jin, Zhengyu; Xue, Huadan; Wan, Yihong; Tian, Jie
|
| Source: INTERNATIONAL JOURNAL OF NANOMEDICINE, 12 8337-8351; 10.2147/IJN.S149235 2017
|
| Language: English
|
| Abstract: An intraoperative technique to accurately identify microscopic tumor residuals could decrease the risk of positive surgical margins. Several lines of evidence support the expression and immunotherapeutie effect of PD-1 in breast cancer. Here, we sought to develop a fluorescence-labeled PD-1 probe for in vivo breast tumor imaging and image-guided surgery. The efficacy of PD-1 monoclonal antibody (PD-1 mAb) as adjuvant immunotherapy after surgery was also assessed. PD-1-I RDyc800CW was developed and examined for its application in tumor imaging and image-guided tumor resection in an immunocompetent 4T1 mouse tumor model. Fluorescence molecular imaging was performed to monitor probe biodistribution and intraoperative imaging. Bioluminescence imaging was performed to monitor tumor growth and evaluate postsurgical tumor residuals, recurrences, and metastases. The PD-1-IRDye800CW exhibited a specific signal at the tumor region compared with the IgG control. Furthermore, PD-1-IRDye800CW-guided surgery combined with PD-1 adjuvant immunotherapy inhibited tumor rcgrowth and microtumor metastases and thus improved survival rate. Our study demonstrates the feasibility of using PD-1-IRDye800CW for breast tumor imaging and image-guided tumor resection. Moreover, PD-1 mAb adjuvant immunotherapy reduces cancer recurrences and metastases emanating from tumor residuals.
|
| ISSN: 1178-2013
|
| IDS Number: FN2IF
|
| Unique ID: WOS:000415814100002
*Click Here to View Full Record
